/
/
ASH 2018: Adding Daratumumab to Velcade/Revlimid/Dex Effective for Newly Diagnosed Multiple Myeloma
ASH 2018: Adding Daratumumab to Velcade/Revlimid/Dex Effective for Newly Diagnosed Multiple Myeloma image
ASH 2018: Adding Daratumumab to Velcade/Revlimid/Dex Effective for Newly Diagnosed Multiple Myeloma
Posted Dec 08, 2018

Patients who combine daratumumab (Dara) with a bortezomib-lenalidomide-low dose dexamethasone (VRd) regimen have deeper, more durable responses to their treatment, experience few significant adverse events and the four drug combination does not affect eligibility for stem cell transplants.

Peter Voorhees from the Levine Cancer Institute reported the findings of a phase 2 study in an oral session at the annual American Society of Hematology (ASH) annual meeting in San Diego, CA on December 1, 2018.  Sixteen patients, all who had at least nine cycles of Dara-VRd and at least three cycles of maintenance, participated in the study.  Dara is a monoclonal antibody that targets the CD-38 antigen that is produced by some myeloma cells.

All patients had a significant response to the Dara-VRd combination and their responses deepened as they went through the stage of induction, consolidation, and maintenance.  At induction, 6% of the participants had a complete response (CR) and 58% had a very good partial response (VGPR).  After maintenance, the response rates were 94% and 100%, respectively.

Although all experienced at least one serious side effect, Dr. Voorhees reported that all were manageable and did not curtail therapy for any patient.  All had successful stem cell mobilization procedures and are eligible for future transplants.

Eight of the patients were measured minimal residual disease (MRD) negative as test through NGS and only one has experienced disease progression.

Dr. Voorhees concluded by observing that the Phase 3 follow-up trial has already completed after enrolling its goal of 200 patients and he expects to report its findings at next year’s ASH meeting in Orlando, FL.

 

The author Greg Brozeit

about the author
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811